First-in-class lupus therapy Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for people with moderate to severe disease.
Developed by UK drugmaker AstraZeneca (LSE: AZN), the treatment is indicated for people with active autoantibody-positive systemic lupus erythematosus (SLE) in the second-line setting.
The approval makes Saphnelo the first biologic for SLE approved in Europe with an indication that is not restricted to patients with a high degree of disease activity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze